Biotechnology company Zealand Pharma A/S (CPH:ZEAL) on Wednesday reported net loss of DKK272.3m, or DKK9.77 per diluted share, for the 12-month period, from 1 January 2017 to 31 December 2017.
This was a 77% decline over net loss of DKK153.9m, or DKK6.33 per diluted share, in 2016.
Revenues for the year were DKK139.8m, down by 40% as compared with DKK234.8m in 2016.
Royalty revenues for the year were DKK38.8m, up by 59% as compared with 2016, while milestone revenues were DKK101.0m, down by 52% as compared with 2016.
Reportedly, these full year results were in line with guidance.
(EUR1.00=DKK7.44)
Bruker Corporation to acquire ELITechGroup for EUR870m, strengthening MDx portfolio
Perrigo announces quarterly dividend increase
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva
Biosenic finalises agreement with Phebra for oral arsenic troxide development